Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ: CPRX )

22.76 +0.21 (+0.93%)
Streaming Delayed Price Updated: 12:24 PM EST, Jan 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 238,774
Open 22.19
Bid (Size) 22.74 (7)
Ask (Size) 22.77 (1)
Prev. Close 22.55
Today's Range 22.07 - 23.14
52wk Range 13.12 - 24.27
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill

Performance

YTD
+5.76%
+5.76%
1 Month
+6.01%
+6.01%
3 Month
+4.12%
+4.12%
6 Month
+30.21%
+30.21%
1 Year
+57.51%
+57.51%

More News

Read More
Unlocking the Growth Potential of NASDAQ:CPRX.
Via Chartmill
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why NASDAQ:CPRX qualifies as a high growth stock.
Via Chartmill
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Via Chartmill
Unlocking the high Growth Potential of NASDAQ:CPRX.
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
NASDAQ:CPRX, an undervalued stock with good fundamentals.
Via Chartmill
BridgeBio Pharma Stock Earns 87 RS Rating
Via Investor's Business Daily
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
Via Investor's Business Daily
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Via Investor's Business Daily
NASDAQ:CPRX, a growth stock which is not overvalued.
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Via Chartmill
Should you consider NASDAQ:CPRX for growth investing?
Via Chartmill
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Via Chartmill
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals.
Via Chartmill
Why NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Via Investor's Business Daily
Don't overlook NASDAQ:CPRX—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.